CYAD Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About Celyad Oncology (EBR: CYAD)
›
Celyad Oncology (EBR: CYAD) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.1610 EUR on 19 November 2026, down 19.5% over 52 weeks. Its 52-week range is 0.1400 EUR to 0.6500 EUR: the price is 75.2% below the high and 15.0% above the low.
At a market capitalisation of 12.06M EUR, it trades at 2.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 94% for CYAD.
Celyad Oncology reports return on equity of 34.1%.
It holds more cash than debt, a net cash position of 121.00K EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.